Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Laule Cornelia, Cohen-Adad Julien, Witt Atlee A, De Luca Gabriele C, Granziera Cristina, Keegan B Mark, Kerbrat Anne, Klawiter Eric C, Kolind Shannon, O'Grady Kristin P, Oh Jiwon, Schilling Kurt G, Sivakolundu Dinesh K, Smith Seth A, Tozlu Ceren, Vavasour Irene M, Bagnato Francesca, Gauthier Susan A, Mainero Caterina, Alonso-Ortiz Eva, Bakshi Rohit, Beck Erin S, Brier Matthew R, Hemond Christopher C, Krieger Stephen, Li David Kb, Shinohara Russell T, Henry Roland G, North American Imaging in Multiple Sclerosis (NAIMS) Cooperative
Аннотация
The spinal cord plays a central role in the pathophysiology and clinical manifestations of multiple sclerosis (MS), yet remains under-studied compared with the brain. This review summarizes key insights from the 2025 North American Imaging in MS Spinal Cord Imaging Workshop, highlighting recent advances, ongoing challenges, and future opportunities in MS spinal cord imaging. We review pathological studies and outline the clinical relevance of spinal cord lesions and atrophy for diagnosis, prognosis, and disease monitoring, highlighting emerging biomarkers of progression independent of relapse activity. Correlations between magnetic resonance imaging, histopathology, and clinical outcomes support the validation and translational potential of advanced spinal cord imaging techniques. Finally, we discuss spinal cord-specific processing pipelines and reproducibility challenges. Collectively, these insights underscore the need to integrate advanced and quantitative spinal cord imaging into clinical trials, research studies, and-when feasible-clinical care, to fully capture the extent of MS pathology, and ultimately improve patient outcomes.